Ionis Pharmaceuticals Inc (NASDAQ:IONS) currently has a daily average trading volume of 1.33M but it saw 1688057 shares traded in last market. With a market cap of 7.57B USD, the company’s current market price of $51.86 came rising about 2.21 while comparing to the previous closing price of $50.74. In past 52 weeks, the stock remained buoying in the range of price level as high as $54.44 and as low as $35.95.
Taking a look at 20-day trading activity of Ionis Pharmaceuticals Inc (IONS) gives us an average price of $48.02, while its current price level is -4.75% below from 52-week high level whereas it is 44.26% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $43.08 while that of 200 days or SMA-200 reads an average of $45.75. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.84% during that period while stretching the period over a month that decreases to 3.55%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 70.30 which implies that the stock is in overbought territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Leerink Partners which upgraded the stock as “Outperform” in its note to investors issued on July 24, 2024, recommending a price target of between $53 and $62 for it. Bernstein also issued its recommendations for the stock as it upgraded the price target for the stock is $44.
Over the week, IONS’s stock price is moving 9.57% up while it is 10.34% when we observe its performance for the past one month. Year-to-date it is 2.51% up and over the past year, the stock is showing an upside performance of 30.14%.
Currently, Ionis Pharmaceuticals Inc’s total number of outstanding shares is 144.34M. Company’s return on investment (ROI) stands at -17.31% and return on equity (ROE) at -98.20%. Stock’s beta reads 0.39. Stock has a price to book (P/B) ratio of 25.51 while price to sale or P/S ratio amounts to 9.74. Its return on asset (ROA) is -13.61% on average.
